CLDN18.2 CAR-T cells eliminate pancreatic cancer cells
Filed with ASX · · 4 pages · English
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Arovella receives R&D tax rebate of $3.21 million
- S&P DJI Announces September 2025 Quarterly Rebalance
- Appendix 4E and Annual Report
- S&P DJI Announces March 2025 Quarterly Rebalance
- Research Agreement with University of North Carolina
Later from Arovella Therapeutics
- Positive FDA Type D Meeting Outcome
- Arovella Therapeutics appoints former CSL CSO Dr Andrew Nash as Non-executive Director
- Quarterly Activities/Appendix 4C Cash Flow Report
- ALA's IND for ALA-101 accepted by the U.S.FDA
- Half Year Report and Appendix 4D
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics